THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB receptor and has been sold online as a designer drug.
However, it is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole. Thus, it is a perfect analog of AM-2201
Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. THJ-2201 is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
Pharmacology of THJ-2201
THJ-2201 acts as a full agonist with a binding affinity of 1.34nM at CB and 1.32nM at CB cannabinoid receptors. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.
It is a drug which acts as a potent but unselective agonist for the cannabinoid receptor CB1 or CB2.
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively. The physiological actions and metabolism of AM2201 have not been characterized.
This product is a qualified Reference Material (RM) that has been manufactured and tested to meet ISO17025 and Guide 34 guidelines. These materials are tested using validated analytical methods on qualified instrumentation to ensure traceability of measurements.